In this regard, we developed a new concise classification of HER2+ BC based on the TNM staging system, a review of the literature, research results, and our clinical experience, dividing the patients into four distinct groups: curable (lymph‐node negative and small (≤3 cm) early breast cancer), do our best to cure (locally advanced or tumors >3 cm early breast cancer), hope for cure (local‐regional recurrent, limited metastases, and exceptional responders), and incurable (metastatic breast cancer with poor performance status or non‐exceptional responders). The gene discussed is ERBB2; the disease is breast cancer.